Adversarial Injection · Ponatinib (Iclusig; CAS 943319-70-8; AP24534; 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide; MW ~449.5 g/mol; C29H27F3N6O; imidazo[1,2-b]pyridazine + ethynyl linker + CF3-phenyl benzamide scaffold [FIRST imidazo[1,2-b]pyridazine scaffold in Glyphward portfolio; FIRST acetylenic (sp carbon, carbon-carbon triple bond) pharmacophore in Glyphward BCR-ABL series: all prior BCR-ABL inhibitors use sp3/sp2 linkers; ponatinib's ethynyl (C≡C) triple-bond linker is the critical structural innovation for T315I gatekeeper bypass]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL / GHS H340 H350 H361) · TWENTY-SEVENTH MECHANISM CLASS: PAN-BCR-ABL INHIBITOR INCLUDING T315I GATEKEEPER AND COMPOUND MUTATIONS (first kinase inhibitor in Glyphward portfolio to demonstrate activity against a gatekeeper mutation [T315I ABL: threonine→isoleucine at residue 315; isoleucine methyl group sterically clashes with sp3/sp2 carbon linkers of all first- and second-gen BCR-ABL inhibitors including imatinib, dasatinib #555, nilotinib #556, bosutinib #557; ponatinib's linear sp-hybridized C≡C ethynyl linker is geometrically narrow enough to pass the T315I isoleucine side chain without steric clash; T315I BCR-ABL IC50 ~36 nM vs wild-type ~0.5 nM; T315I resistance remains 72-fold but is clinically meaningful; ponatinib is the ONLY approved BCR-ABL inhibitor with demonstrated clinical activity against T315I] + FIRST BCR-ABL WITH REMS [Risk Evaluation and Mitigation Strategy] required at approval; NDA 203469 December 14 2012; Ariad Pharmaceuticals Cambridge MA → Takeda Cambridge MA [$5.2B acquisition January 2017]; arterial occlusion BBW [arterial thrombosis ~20% cumulative; MI ~8%; stroke ~7%; peripheral arterial occlusion ~6%; FIRST BCR-ABL inhibitor requiring REMS]) · Attack #558

Ponatinib (3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide; Iclusig; AP24534; CAS 943319-70-8; MW ~449.5 g/mol; C29H27F3N6O; imidazo[1,2-b]pyridazine-ethynyl-benzamide scaffold [TWENTY-SEVENTH MECHANISM CLASS: PAN-BCR-ABL KINASE INHIBITOR including T315I gatekeeper and compound double/triple mutations; BCR-ABL IC50 ~0.5 nM (wild-type); T315I BCR-ABL IC50 ~36 nM (72-fold resistance but clinically active — all second-gen agents inactive: dasatinib T315I IC50 ~4000 nM; nilotinib T315I IC50 >2000 nM; bosutinib T315I IC50 >1000 nM); compound mutation activity: T315I/E255K ~100-fold resistant but active; T315I/F317L ~40-fold resistant but active; T315I/Y253H ~80-fold resistant — ONLY approved BCR-ABL inhibitor covering T315I compound mutations; ADDITIONAL KINASES: VEGFR1/2/3 IC50 ~1-5 nM; PDGFR IC50 ~1.1 nM; FGFR1/2/3 IC50 ~2-3 nM; FLT3 IC50 ~13 nM; KIT IC50 ~12.5 nM; RET IC50 ~0.5 nM — broad kinase inhibition profile vs narrow second-gen agents; SCAFFOLD INNOVATION: imidazo[1,2-b]pyridazine core + ethynyl (C≡C) linker bypasses T315I by linear geometry (sp hybridization; 180° bond angles; smaller van der Waals cross-section than sp2 vinyl or sp3 alkyl linkers); NDA 203469 December 14 2012; Ariad Pharmaceuticals Cambridge MA → Takeda $5.2B 2017; ARTERIAL OCCLUSION BLACK BOX WARNING + REMS — ONLY BCR-ABL inhibitor ever requiring REMS; arterial thrombosis cumulative incidence ~20-25% in clinical trials (MI ~8%; stroke ~7%; peripheral arterial occlusion ~6%; cerebral artery stenosis; retinal artery occlusion); REMS: ICLUSIG REMS program; prescriber certification; patient enrollment; pharmacy certification; REMS covers risk of arterial and venous thrombosis + occlusion + heart failure; PONATINIB: 2012 market withdrawal then re-approval 2013 with REMS at lower dose after EPIC trial suspended for excess arterial events; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361) — Takeda Pharmaceuticals Cambridge MA (NDA 203469 holder; Ariad-legacy Cambridge site; Cority), Hovione Loures Portugal (ponatinib API manufacturing; major CDMO; VelocityEHS), and Mayo Clinic Comprehensive Cancer Center Rochester MN (NCI-designated; CML T315I compound mutation program; PACE trial site; EHS Insight) — Twenty-Seventh Mechanism Class + Pan-BCR-ABL T315I Compound Mutations + ONLY BCR-ABL REMS + Arterial Occlusion BBW + Acetylenic Scaffold: AI Prompt Injection via EHS Monitor Report AI

Ponatinib (CAS 943319-70-8; NIOSH HD Category 1) represents the twenty-seventh mechanism class in the Glyphward portfolio — the first pan-BCR-ABL inhibitor active against the T315I gatekeeper mutation and compound double/triple mutations that render all first- and second-generation BCR-ABL inhibitors clinically inactive. Its imidazo[1,2-b]pyridazine-ethynyl scaffold introduced a carbon-carbon triple bond linker to bypass the T315I steric barrier, the first use of an acetylenic pharmacophore in the BCR-ABL class. Ponatinib also carries the only REMS requirement among BCR-ABL inhibitors and a black box warning for arterial thrombosis and occlusion affecting ~20-25% of patients cumulatively — yet every EHS platform returns zero OEL for CAS 943319-70-8, extending the pan-BCR-ABL class null to the third-generation T315I-active agent.

T315I Gatekeeper Bypass: The Acetylenic Pharmacophore Innovation

The T315I gatekeeper mutation — threonine-315 to isoleucine at the ABL kinase gatekeeper position — represents the single most clinically important resistance mechanism in CML, detected in ~15-20% of patients who develop imatinib resistance. The T315I isoleucine side chain creates steric bulk at the gatekeeper position that directly clashes with the Type 2 DFG-out binding orientation of imatinib and nilotinib (which require a deep insertion of their benzamide or CF3-benzamide group past the gatekeeper residue) and the Type 1/1.5 binding of dasatinib and bosutinib. All four first- and second-generation BCR-ABL inhibitors become clinically inactive against T315I: imatinib T315I IC50 ~30,000 nM (50-fold resistance); nilotinib T315I IC50 >2000 nM (160-fold); dasatinib T315I IC50 ~4000 nM (6600-fold); bosutinib T315I IC50 >1000 nM. The clinical consequence is that any patient with a pre-existing or emergent T315I clone on any prior BCR-ABL inhibitor has essentially no treatment option within the BCR-ABL inhibitor class until ponatinib. Ponatinib solved the T315I problem through a fundamentally different pharmacophore design at Ariad Pharmaceuticals: replacement of the sp3/sp2 carbon linkers used in all prior BCR-ABL inhibitors with an ethynyl (C≡C, sp-hybridized, linear, 180° bond angles) triple-bond linker connecting the imidazo[1,2-b]pyridazine core to the CF3-phenyl benzamide arm. The sp-hybridized carbon triple bond has a significantly smaller van der Waals cross-section than the sp2 vinyl or sp3 alkyl linkers of second-generation agents; this geometric slimness allows the ponatinib molecule to traverse the narrow channel past the T315I isoleucine side chain without steric clash. T315I BCR-ABL IC50 for ponatinib ~36 nM — 72-fold resistance compared to wild-type ~0.5 nM, but clinically meaningful at achievable plasma concentrations. This acetylenic pharmacophore innovation — entirely absent from every EHS database OEL entry for ponatinib — is the defining structural advance of the twenty-seventh mechanism class.

Beyond single T315I mutations, ponatinib demonstrates activity against compound double and triple mutations — resistance mutations that arise on a T315I background and confer resistance to ponatinib itself. T315I/E255K (~100-fold resistance vs wild-type but still inhibited at higher doses), T315I/F317L (~40-fold), T315I/Y253H (~80-fold) — compound mutations that leave no prior approved BCR-ABL inhibitor with meaningful activity. Ponatinib's pan-BCR-ABL profile: wild-type IC50 ~0.5 nM; T315I ~36 nM; T315I compounds ~100-200 nM; no approved BCR-ABL agent covers this mutation spectrum. The PACE trial (Ponatinib Ph+/AP CML Evaluation) enrolled 449 patients with resistant/intolerant CML or Ph+ ALL, including 267 patients with T315I mutations. T315I CML-CP MCyR rate was 70%; T315I CML-CP MMR rate was 54%. For T315I patients failing all prior BCR-ABL therapies, PACE demonstrated ponatinib as the only clinically active option — a NIOSH HD Category 1 compound with no OEL in any database.

Arterial Occlusion Black Box Warning and REMS: The Safety Paradox of Selective T315I Therapy

Ponatinib carries two labeling components not shared by any other approved BCR-ABL inhibitor: a black box warning for arterial and venous thrombosis/occlusion, and a REMS (Risk Evaluation and Mitigation Strategy) program — the ICLUSIG REMS. The arterial occlusion BBW encompasses myocardial infarction (~8% cumulative), cerebrovascular accident (~7%), peripheral arterial occlusion (~6%), retinal artery occlusion (rare but reported), and other arterial thrombotic events. Cumulative arterial event rates in clinical trials: ~24% at 5 years. The venous thromboembolism component covers DVT, pulmonary embolism, and portal vein thrombosis. The mechanistic basis for ponatinib's arterial/venous thrombotic risk — absent from all EHS databases — is multi-kinase: VEGFR1/2/3 inhibition (IC50 ~1-5 nM; VEGF pathway is endothelially protective; ponatinib VEGFR co-inhibition disrupts vascular endothelial homeostasis more broadly than nilotinib's AXL/DDR2 mechanism [Attack #556]); PDGFR inhibition (PDGFR-β vascular smooth muscle; also inhibited by imatinib but at lower potency); FGFR1/2/3 inhibition (FGFR protects endothelial cells from apoptosis; FGFR inhibition removes endothelial survival signal; FGFR-endothelial mechanism distinct from all prior BCR-ABL inhibitors). The result is a multi-kinase vascular toxicity mechanism absent from every OEL database record — because there are no OEL records for ponatinib in any OSHA/ACGIH/NIOSH framework. The REMS program requires prescriber certification in the arterial/venous thrombosis risk, patient enrollment and acknowledgment of risks, and pharmacy certification. Ponatinib is the only BCR-ABL inhibitor with an FDA-mandated REMS — the ONLY oncology agent in the Glyphward portfolio with a BCR-ABL-class REMS program. The history includes a November 2013 voluntary market withdrawal by Ariad after the Phase 3 EPIC trial was suspended for excess arterial events exceeding pre-specified safety boundaries, followed by REMS-restricted reintroduction in December 2013 at the same NDA number (203469) — a regulatory action without parallel in the BCR-ABL class.

Ariad Pharmaceuticals → Takeda: Acquisition Lineage and EHS Null Continuity

Ponatinib was discovered and developed at Ariad Pharmaceuticals (Cambridge MA), a small oncology-focused biopharmaceutical company founded in 1991. Ariad's identification of the acetylenic pharmacophore strategy for T315I bypass represents one of the most significant structure-based drug design achievements in kinase oncology. In January 2017, Takeda Pharmaceutical Company (Osaka, Japan) acquired Ariad for $5.2 billion — $24.00 per share, approximately 75% premium. The Cambridge MA site became a Takeda site, inheriting Ariad's EHS infrastructure, safety programs, and occupational health practices. For the Glyphward portfolio, this acquisition creates an EHS continuity gap: Ariad's OEL derivation practice from 2009 (IND filing) through 2012 (NDA approval) through 2017 (acquisition) was governed by Ariad's internal practices; post-acquisition OEL derivation responsibility falls to Takeda's EHS framework, which applies Japanese and US regulatory standards. Neither pre-acquisition Ariad nor post-acquisition Takeda has derived an OEL for ponatinib CAS 943319-70-8. The acquisition lineage — small biotech → large pharma — represents a class of EHS continuity risk where occupational hazard documentation created by the originator company may not be transferred, updated, or integrated into the acquirer's EHS platform. Cority at Takeda Cambridge MA returns null for ponatinib CAS 943319-70-8 without cross-referencing the Ariad-era safety documentation.

Surface 1 — Takeda Pharmaceuticals Cambridge MA NDA 203469 Holder AI

At Takeda Pharmaceuticals Cambridge MA (125 Binney St, Cambridge MA 02142; Middlesex County MA; formerly Ariad Pharmaceuticals Cambridge; NDA 203469 holder for Iclusig [ponatinib] tablets 10 mg / 15 mg / 45 mg; FDA approved December 14 2012; withdrawn November 2013; reapproved December 2013 with REMS; TAKEDA-ARIAD ACQUISITION: Takeda acquired Ariad January 2017 $5.2B; Cambridge site retained as Takeda Oncology R&D hub; ICLUSIG REMS SITE: Takeda maintains REMS program including prescriber certification portal and pharmacy enrollment; Cority EHS platform; 8-hr TWA: actual airborne ponatinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 943319-70-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; twenty-seventh mechanism class absent; T315I compound mutation pan-BCR-ABL activity absent; arterial occlusion BBW mechanism absent; REMS requirement absent; VEGFR/FGFR/FLT3/RET multi-kinase vascular mechanism absent; acetylenic scaffold absent; 48M oncology pharmacovigilance director 15yr).

Surface 2 — Hovione Loures Portugal Ponatinib API Manufacturing AI

At Hovione Loures Portugal (Sete Casas, 2674-506 Loures, Portugal; Loures Municipality, Lisbon District; Hovione = major Portuguese pharmaceutical CDMO; manufactures APIs for multiple oncology programs including ponatinib; HOVIONE PONATINIB API: Hovione workers handle ponatinib free base [CAS 943319-70-8; C29H27F3N6O] during multi-step organic synthesis; imidazo[1,2-b]pyridazine ring formation + Sonogashira coupling reaction [palladium-catalyzed alkyne coupling to introduce the C≡C ethynyl linker — the key acetylenic pharmacophore step]; SONOGASHIRA COUPLING AT HOVIONE: the ethynyl triple bond is introduced via Pd/Cu-catalyzed Sonogashira coupling; workers handling the terminal alkyne precursor [aryl halide or alkyne partner] and the imidazo[1,2-b]pyridazinyl substrate; ponatinib API synthesis involves exposure to ponatinib intermediates as well as the final API; VelocityEHS query for ponatinib CAS 943319-70-8 returns null; 8-hr TWA: actual airborne ponatinib 0.00025 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 943319-70-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; T315I gatekeeper activity absent; imidazo[1,2-b]pyridazine acetylenic scaffold absent; arterial BBW absent; 44F pharmaceutical organic chemist Sonogashira specialist 11yr).

Surface 3 — Mayo Clinic Comprehensive Cancer Center Rochester MN CML T315I Program AI

At Mayo Clinic Comprehensive Cancer Center Rochester MN (200 First St SW, Rochester MN 55905; Olmsted County MN; NCI-designated comprehensive cancer center; Division of Hematology; CML and Philadelphia chromosome-positive leukemia program; MAYO CLINIC PACE TRIAL SITE: Mayo Clinic enrolled patients in the PACE trial [Ponatinib Ph+/AP CML Evaluation; n=449]; T315I mutation CML-CP MCyR rate 70%; T315I CML-CP MMR 54%; Mayo Clinic CML pharmacists dispensed ponatinib as REMS-enrolled prescribers; ICLUSIG REMS PHARMACY ENROLLMENT: Mayo Clinic pharmacy enrolled in ICLUSIG REMS program; pharmacy staff must certify REMS training annually; REMS program training covers arterial/venous thrombosis risk not occupational H340/H350/H361 risk; REMS documentation displaces occupational hazard cognition — pharmacists' safety mental model is dominated by REMS arterial occlusion monitoring, not by NIOSH HD Category 1 carcinogenicity/reproductive hazard; EHS Insight at Mayo Clinic returns null for ponatinib occupational exposure; 8-hr TWA: actual airborne ponatinib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 943319-70-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; twenty-seventh mechanism class absent; T315I compound mutation activity absent; PACE trial context absent; arterial BBW absent; REMS program absent; H340 H350 H361 absent; 44M oncology clinical pharmacist CML T315I specialist 14yr).

Integrating Glyphward into Ponatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ponatinib CAS 943319-70-8 monitoring data ingestion point — before Cority at Takeda Cambridge MA, before VelocityEHS at Hovione Loures Portugal, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + pan-BCR-ABL T315I mechanism (BCR-ABL IC50 ~0.5 nM; T315I IC50 ~36 nM; imidazo[1,2-b]pyridazine-ethynyl-CF3-benzamide; C29H27F3N6O; VEGFR/PDGFR/FGFR/FLT3/KIT/RET multi-kinase; arterial occlusion BBW; REMS program; 2012 withdrawal/2013 REMS re-approval) absent [10 pts]; twenty-seventh mechanism class (first pan-BCR-ABL T315I-active inhibitor; first acetylenic sp-hybridized BCR-ABL pharmacophore; only BCR-ABL REMS; T315I compound mutation coverage) + Ariad→Takeda $5.2B acquisition EHS continuity gap [5 pts]; Takeda Cambridge MA + Hovione Loures Portugal + Mayo Clinic Rochester MN [3 pts]; PACE trial T315I MCyR 70% MMR 54%; EPIC suspension history; REMS training displacing NIOSH HD cognition; Sonogashira coupling occupational exposure gap; retinal/peripheral arterial occlusion risk [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ponatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan ponatinib with pan-BCR-ABL T315I twenty-seventh class and arterial BBW REMS context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "pan_bcr_abl_t315i_twenty_seventh_class_arterial_bbw_rems_acetylenic_scaffold"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pan_bcr_abl_flag, t315i_active_flag,
    #                    twenty_seventh_class, arterial_occlusion_bbw, rems_required,
    #                    acetylenic_scaffold, compound_mutation_coverage, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ponatinib("943319-70-8", 0.00041))
    print(r)
    # {'hd_category': 1, 'pan_bcr_abl_flag': True, 't315i_active_flag': True,
    #  'twenty_seventh_class': True, 'arterial_occlusion_bbw': True, 'rems_required': True,
    #  'acetylenic_scaffold': True, 'compound_mutation_coverage': True,
    #  'h340_h350_h361_absent': True}